965 related articles for article (PubMed ID: 17888634)
1. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).
Appelbaum PC
Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
Fritsche TR; Rhomberg PR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
[TBL] [Abstract][Full Text] [Related]
3. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
4. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
5. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA).
Howden BP
Intern Med J; 2005 Dec; 35 Suppl 2():S136-40. PubMed ID: 16271057
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates.
Hussain FM; Boyle-Vavra S; Shete PB; Daum RS
J Infect Dis; 2002 Sep; 186(5):661-7. PubMed ID: 12195353
[TBL] [Abstract][Full Text] [Related]
7. Clonal dissemination of meticillin-resistant and vancomycin-intermediate Staphylococcus aureus in a Taiwanese hospital.
Hsueh PR; Lee SY; Perng CL; Chang TY; Lu JJ
Int J Antimicrob Agents; 2010 Oct; 36(4):307-12. PubMed ID: 20685086
[TBL] [Abstract][Full Text] [Related]
8. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
[TBL] [Abstract][Full Text] [Related]
9. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
11. [Searching for Staphylococcus aureus strains with reduced susceptibility to glycopeptides among clinical isolates obtained during the year of 2002].
Młynarczyk A; Młynarczyk G; Łuczak M
Med Dosw Mikrobiol; 2003; 55(3):209-17. PubMed ID: 14702662
[TBL] [Abstract][Full Text] [Related]
12. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
13. Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.
Franchi D; Climo MW; Wong AH; Edmond MB; Wenzel RP
Clin Infect Dis; 1999 Dec; 29(6):1566-8. PubMed ID: 10585815
[TBL] [Abstract][Full Text] [Related]
14. Glycopeptide resistant Staphylococcus.
Witte W
J Vet Med B Infect Dis Vet Public Health; 2004; 51(8-9):370-3. PubMed ID: 15525368
[TBL] [Abstract][Full Text] [Related]
15. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
[TBL] [Abstract][Full Text] [Related]
16. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital.
Sancak B; Ercis S; Menemenlioglu D; Colakoglu S; Hasçelik G
J Antimicrob Chemother; 2005 Sep; 56(3):519-23. PubMed ID: 16046461
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
Steinkraus G; White R; Friedrich L
J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.
Fridkin SK
Clin Infect Dis; 2001 Jan; 32(1):108-15. PubMed ID: 11118389
[TBL] [Abstract][Full Text] [Related]
19. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.
Hawser SP; Bouchillon SK; Hoban DJ; Dowzicky M; Babinchak T
Int J Antimicrob Agents; 2011 Mar; 37(3):219-24. PubMed ID: 21239146
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.
Nonhoff C; Denis O; Struelens MJ
Clin Microbiol Infect; 2005 Mar; 11(3):214-20. PubMed ID: 15715719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
